Phase 4 N=150 ESP Block for Post Cesarean Analgesia
Cesarean Section Complications
Primary: Postoperative Oxycodone Consumption 0- 48 Hours After Cesarean Delivery — 12.5; 25 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=65 Singing and Cardiovascular Health in Older Adults
Cardiovascular Diseases · Cardiovascular Risk Factor · Cardiovascular Health
Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864
Phase 2 N=56 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
N/A N=12 Automated Reinforcement Management System (ARMS)
Alcohol Use Disorder
Primary: Biochemically Measured Change in Alcohol Abstinence. — 347; 615; 209 Number of negative BAC samples by phase.
N/A N=266 Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer
Cancer
Primary: Completion of Palliative Care Visit — 11; 19 Participants
Phase 4 N=81 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
Bacterial Vaginosis
Primary: Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests — 5.59; 5.22; 4.91; 7.41 log10 copies/ml — p=0.011
Phase 3 N=300 Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
HIV · Smoking Cessation
Primary: 7-day Abstinence — 4; 17; 15; 29 Participants
Phase 4 N=212 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths — 106; 1; 0…
N/A N=275 A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Metastatic Melanoma
Primary: Overall Survival (OS) — 33.6; 24.0 Months
N/A N=75 Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients
COVID-19
Primary: Gut Microbiome — 51.87; 46.1; 29.43; 29.77 Mean percentages of gut microbiota units — p=<0.05
Phase 4 N=10 Short-term B-cell Depletion in Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
N/A N=1,139 Working to Increase Stability Through Exercise
Fractures, Bone · Serious Fall-related Injuries
Primary: Number of Participants Experiencing a Serious Fall-Related Injury (SFI) — 186; 166 Participants — p=0.43
N/A N=127 Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes
Dietary Habits
Primary: Change From Baseline Hemoglobin A1c at 12 Weeks — -0.3; -0.1 % of HbA1c
Phase 3 N=129 Starting a Testosterone and Exercise Program After Hip Injury
Hip Fracture · Frailty · Sarcopenia
Primary: Change in Six Minute Walk Distance — 42.69; 40.50; 37.65; 42.38 Meters — p=0.853
N/A N=134 STAR Caregivers - Virtual Training and Follow-up
Alzheimer Disease · Dementia · Caregiver Burnout
Primary: Change in Caregiver Burden — 24.44; 22.30 units on a scale — p=0.97